-
Posted by
Two Blokes May 1 -
Filed in
Stock
-
0 views
Topline results from phase 3 sunRIZE study, using ersodetug for the treatment of patients with congenital hyperinsulinism, expected in December 2025. Proof-of-concept was established in a phase 2 study using the oral small molecule plasma kallikrein inhibitor RZ402 for the treatment of patients with diabetic macular edema. The global diabetic macular edema market size is projected to reach $7.5 billion by 2034.
